Frequently Asked Questions about Kura Oncology, Inc. (KURA)

Name: Kura Oncology, Inc. (KURA) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Kura Oncology, Inc. (KURA) do?

Accepted Answer

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the...

Question 2

Is Kura Oncology, Inc. (KURA) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of KURA reveals an Altman Z-Score of -1.64 and a Piotroski F-Score of 2/9. These metrics, combined with its 5-year revenue trend ($0.07B most recent), help investors decide if KURA fits their risk profile.

Question 3

What is the current P/E ratio for KURA?

Accepted Answer

As of the latest trading session, Kura Oncology, Inc. (KURA) has a trailing P/E ratio of -2.79.

Question 4

Who is the CEO of Kura Oncology, Inc.?

Accepted Answer

The current Chief Executive Officer of Kura Oncology, Inc. is Troy Edward Wilson.

Question 5

What was KURA's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Kura Oncology, Inc. reported annual revenues of $0.07B (2025), $0.05B (2024), $0.00B (2023), $0.00B (2022), $0.00B (2021) respectively.

Question 6

Does KURA pay a dividend?

Accepted Answer

Kura Oncology, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does KURA have?

Accepted Answer

In its latest reporting period, Kura Oncology, Inc. generated $-0.07B in Free Cash Flow against a total debt load of $0.02B.

Question 8

What is the Price-to-Book (P/B) ratio of Kura Oncology, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Kura Oncology, Inc. (KURA) is currently 4.46.

Question 9

What is the Price-to-Sales (P/S) ratio of KURA?

Accepted Answer

Based on trailing twelve-month data, Kura Oncology, Inc. (KURA) trades at a Price-to-Sales (P/S) ratio of 11.54.

Question 10

What is Kura Oncology, Inc.'s Return on Equity (ROE)?

Accepted Answer

Kura Oncology, Inc. (KURA) has a Return on Equity (ROE) of -102.59%, representing its profitability relative to shareholder equity.

Period	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt
2025-12	738.4M	564.2M	174.1M	20.5M	-128.6M
2024-12	760.2M	346.5M	413.6M	16.6M	-207.9M
2023-12	448.9M	51.7M	397.3M	17.2M	-20.1M
2022-12	456.3M	36M	420.3M	14M	-37.8M
2021-12	534.1M	27.4M	506.6M	6.9M	-83.8M

Period	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt
2025-12	738.4M	564.2M	174.1M	20.5M	-128.6M
2024-12	760.2M	346.5M	413.6M	16.6M	-207.9M
2023-12	448.9M	51.7M	397.3M	17.2M	-20.1M
2022-12	456.3M	36M	420.3M	14M	-37.8M
2021-12	534.1M	27.4M	506.6M	6.9M	-83.8M